Daphne Koller, Getty

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

Bris­tol My­ers Squibb is turn­ing to one of the star up­starts in the ma­chine learn­ing world to go back to the draw­ing board and come up with the dis­ease mod­els need­ed to find drugs that can work against two of the tough­est tar­gets in the neu­ro world.

Daphne Koller’s well-fund­ed in­sitro is get­ting $70 mil­lion in cash and near-term mile­stones to use their ma­chine learn­ing plat­form to cre­ate in­duced pluripo­tent stem cell-de­rived dis­ease mod­els for ALS and fron­totem­po­ral de­men­tia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.